HHS announces major workforce cuts and reorganisation
The US Department of Health and Human Services (HHS) will cut 10,000 full-time employees and restructure its divisions as part…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a news and features reporter for Pharmaceutical Technology. Jenna holds a BSc in Biochemistry and has interests in rare diseases, gene therapies, and oncology. Contact Jenna
-
-
UKHSA unveils high-risk pathogen list to drive innovation
The UK Health and Security Agency (UKHSA) has released a new watch list of 24 infectious diseases that could pose…
-
The trillion-dollar opportunity in women’s health
Closing the gap in health interventions between men and women could add $1tn to the global gross domestic product (GDP)…
-
Whole genome sequencing poised to transform newborn screening programmes
Newborn screening is transforming, as advances in genomic sequencing pave the way for earlier, more accurate diagnoses of rare diseases.…
-
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’…
-
People-focused cancer care demands policy support
Access to high-quality cancer care remains deeply uneven worldwide. While advances in cancer treatment and diagnostics are improving survival rates…
-
How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and Eisai…
-
Exact Sciences showcases early cancer detection test data at AACR meeting
Exact Sciences has unveiled new findings from a case-control study demonstrating the potential of its advanced multi-biomarker class approach to…
-
Sinaptica hails neuromodulation a “renaissance” in Alzheimer’s treatment
Fresh off positive data presented at the Clinical Trials on Alzheimer’s Disease 2024 (CTAD) conference earlier this month, Sinaptica’s CEO,…
-
Nevro secures CE mark for AI-based spinal cord stimulation system
US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord stimulation…
